Moreover, trametinib, a MEK inhibitor, can promote the expression of TIM-3, resulting in decreased CD8 + T cells, while anti-TIM-3 monoclonal antibody enhances anti-tumor immune function by stimulating CD8+ T cells, and reverses the depletion of T and NK cells in the trametinib-induced immune microenvironment. The gene discussed is HAVCR2; the disease is neoplasm.